Institution
Forest Research Institute
Facility•Dehra Dūn, India•
About: Forest Research Institute is a facility organization based out in Dehra Dūn, India. It is known for research contribution in the topics: Population & Forest management. The organization has 5320 authors who have published 7625 publications receiving 185876 citations.
Topics: Population, Forest management, Picea abies, Forest ecology, Scots pine
Papers published on a yearly basis
Papers
More filters
••
TL;DR: Woody species are indispensable sources of animal feed in southern Europe, particularly in areas with dry to semi-dry Mediterranean climates, and are nutritionally superior to most spontaneous species and methods of strategically integrating them into Mediterranean production systems are discussed.
125 citations
••
TL;DR: Clear-cuts may support assemblages of species associated with natural disturbances, if suitable substrates are available, and long-term monitoring of logs by saproxylic beetles will determine their lifetime conservation value.
125 citations
••
TL;DR: Effets de l'enrichissement en CO 2 atmospherique observe sur 4 clones de peupliers du point de vue modification des proprietes des surfaces foliaires: densite des cellules epidermiques, densite et taille des tomates et conductance stomatique.
125 citations
••
TL;DR: Memantine reduces the levels of Aβ peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Aβ in mammalian brains and have therapeutic implications for neurodegenerative disorders.
Abstract: Memantine is a moderate-affinity, uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist that stabilizes cognitive, functional, and behavioral decline in patients with moderate to severe Alzheimer's disease (AD). In AD, the extracellular deposition of fibrillogenic amyloid-beta peptides (Abeta) occurs as a result of aberrant processing of the full-length Abeta precursor protein (APP). Memantine protects neurons from the neurotoxic effects of Abeta and improves cognition in transgenic mice with high brain levels of Abeta. However, it is unknown how memantine protects cells against neurodegeneration and affects APP processing and Abeta production. We report the effects of memantine in three different systems. In human neuroblastoma cells, memantine, at therapeutically relevant concentrations (1-4 muM), decreased levels of secreted APP and Abeta(1-40). Levels of the potentially amylodogenic Abeta(1-42) were undetectable in these cells. In primary rat cortical neuronal cultures, memantine treatment lowered Abeta(1-42) secretion. At the concentrations used, memantine treatment was not toxic to neuroblastoma or primary cultures and increased cell viability and/or metabolic activity under certain conditions. In APP/presenilin-1 (PS1) transgenic mice exhibiting high brain levels of Abeta(1-42), oral dosing of memantine (20 mg/kg/day for 8 days) produced a plasma drug concentration of 0.96 microM and significantly reduced the cortical levels of soluble Abeta(1-42). The ratio of Abeta(1-40)/Abeta(1-42) increased in treated mice, suggesting effects on the gamma-secretase complex. Thus, memantine reduces the levels of Abeta peptides at therapeutic concentrations and may inhibit the accumulation of fibrillogenic Abeta in mammalian brains. Memantine's ability to preserve neuronal cells against neurodegeneration, to increase metabolic activity, and to lower Abeta level has therapeutic implications for neurodegenerative disorders.
125 citations
••
TL;DR: Extended-release memantine was efficacious, safe, and well tolerated in this population of patients with moderate-to-severe Alzheimer’s disease concurrently taking cholinesterase inhibitors.
Abstract: Immediate-release memantine (10 mg, twice daily) is approved in the USA for moderate-to-severe Alzheimer’s disease (AD). This study evaluated the efficacy, safety, and tolerability of a higher-dose, once-daily, extended-release formulation in patients with moderate-to-severe AD concurrently taking cholinesterase inhibitors. In this 24-week, double-blind, multinational study (NCT00322153), outpatients with AD (Mini-Mental State Examination scores of 3–14) were randomized to receive once-daily, 28-mg, extended-release memantine or placebo. Co-primary efficacy parameters were the baseline-to-endpoint score change on the Severe Impairment Battery (SIB) and the endpoint score on the Clinician’s Interview-Based Impression of Change Plus Caregiver Input (CIBIC-Plus). The secondary efficacy parameter was the baseline-to-endpoint score change on the 19-item Alzheimer’s Disease Cooperative Study–Activities of Daily Living (ADCS–ADL19); additional parameters included the baseline-to-endpoint score changes on the Neuropsychiatric Inventory (NPI) and verbal fluency test. Data were analyzed using a two-way analysis of covariance model, except for CIBIC-Plus (Cochran–Mantel–Haenszel test). Safety and tolerability were assessed through adverse events and physical and laboratory examinations. A total of 677 patients were randomized to receive extended-release memantine (n = 342) or placebo (n = 335); completion rates were 79.8 and 81.2 %, respectively. At endpoint (week 24, last observation carried forward), memantine-treated patients significantly outperformed placebo-treated patients on the SIB (least squares mean difference [95 % CI] 2.6 [1.0, 4.2]; p = 0.001), CIBIC-Plus (p = 0.008), NPI (p = 0.005), and verbal fluency test (p = 0.004); the effect did not achieve significance on ADCS–ADL19 (p = 0.177). Adverse events with a frequency of ≥5.0 % that were more prevalent in the memantine group were headache (5.6 vs. 5.1 %) and diarrhea (5.0 vs. 3.9 %). Extended-release memantine was efficacious, safe, and well tolerated in this population.
124 citations
Authors
Showing all 5332 results
Name | H-index | Papers | Citations |
---|---|---|---|
Kari Alitalo | 174 | 817 | 114231 |
Jaakko Kaprio | 163 | 1532 | 126320 |
Glenn D. Prestwich | 88 | 690 | 42758 |
John K. Volkman | 78 | 212 | 21931 |
Petri T. Kovanen | 77 | 432 | 27171 |
Hailong Wang | 69 | 647 | 19652 |
Mika Ala-Korpela | 65 | 319 | 18048 |
Heikki Henttonen | 64 | 271 | 14536 |
Zhihong Xu | 57 | 438 | 11832 |
Kari Pulkki | 54 | 215 | 11166 |
Louis A. Schipper | 53 | 192 | 9224 |
Sang Young Lee | 53 | 271 | 9917 |
Young-Joon Ahn | 52 | 288 | 9121 |
Venkatesh Narayanamurti | 49 | 258 | 9399 |
Francis M. Kelliher | 49 | 124 | 8599 |